Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia and Ejection Fraction > 35%

NCT05549752 is registered in ClinicalTrials.gov with Hippocration General Hospital as lead sponsor.

NCT NCT05549752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05549752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia and Ejection Fraction > 35%
Lead sponsor
Hippocration General Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
March 24, 2023
Completion date
January 30, 2026
Enrollment
80 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation paroxysmal, coronary artery disease without residual ischemia